anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Incontinence-associated dermatitis (IAD) is an irritant contact dermatitis from prolonged contact with urine or faeces, which can significantly impact patient comfort and quality of life. The identification of prognostic factors for the development of IAD has the potential to enhance management, support preventive measures and guide future research. The objective of this systematic review was to summarize the empirical evidence of prognostic factors for the development of IAD. This study included prospective and retrospective observational studies or clinical trials that described prognostic factors associated with IAD. There were no restrictions on setting, time, language, participants or geographical regions. Exclusion criteria included reviews, editorials, commentaries, methodological articles, letters to the editor, cross-sectional and case-control studies, and case reports. Searches were conducted from inception to April 2024 on MEDLINE, CINAHL, EMBASE and the Cochrane Library. The studies were assessed by two independent reviewers using the QUIPS and the CHARMS-PF for data extraction. A narrative synthesis approach was employed due to study heterogeneity and using the 'vote counting based on direction' method and the sign test. The overall certainty of evidence was assessed using adapted GRADE criteria. The review included 12 studies and identified 15 potential predictors. Moderate-quality evidence suggests that increased stool frequency, limited mobility and friction/shear problems are risk factors for IAD development. Female sex, older age, vasopressor use and loose/liquid stool are risk factors supported by low-quality evidence. Increased stool frequency, limited mobility and friction/shear problems seem to be risk factors for the development of IAD. There is insufficient evidence to support the predictive validity of female sex, older age, loose/liquid stool and vasopressor use. There is substantial methodological variability across studies, making it challenging to make comparisons. Large-scale cohort studies in different settings that incorporate our review findings should be conducted in the future.
PURPOSE:To obtain an abnormal shadow detection output device with which the suing performance is not deteriorated by installing an abnormal shadow detecting part, having a transmission means for transmitting the abnormal shadow data, and an image output part, having a receiving means for receiving the image data and abnormal shadow data, and an image output means for outputting the regenerated image based on the image data and the information based on the abnormal shadow data. CONSTITUTION:The image data SD is inputted into the tumor image detecting means 11 in a tumor image detecting part 10 as one example of an abnormal shadow detecting part. In the tumor shadow detecting means 11, calculation is executed on the basis of the image data SD, and the image data SD' which represents emphasized tumor shadow image in which the tumor shadow in X ray image corresponding to the image data SD is emphasized is generated. The generated image data SD' is transmitted to three image display parts 40, 40' and 40'' through a transmitter 12. The visual image based on the image data SD', i.e., the X-ray image in which the tumor shadow is emphasized is displayed on the CRT displays 40, 40', and 40''. An operator can vary the threshold value Th1 by operating keyboards 43, 43', and 43'', and the image elements which satisfy the relation SD'>=Th1 is judged as the tumor shadow in large measure, and distinctly displayed particularly, and the count value is displayed at the corner of a screen.
OBJECTIVES: To assess the prevalence of urinary incontinence and the clinical and demographic factors associated with patients with Post-COVID-19 Syndrome.
METHOD: A cross-sectional study was conducted with 59 participants from Porto Alegre/RS. Data were collected via telephone interviews using a structured instrument, the Functional Status Scale, and the International Consultation on Incontinence Questionnaire - Short Form, between September 2021 and October 2022. Numerical data were analyzed for normality using the Shapiro-Wilk test. Student's t-test with Mann-Whitney's post-hoc was applied for comparison of continuous variables. Fisher's exact test was used for correlation of categorical data.
RESULTS: The sample included 32 women (56.4 ± 11.3 years) and 27 men (49.5 ± 10.7 years). Only women reported post-COVID-19 urinary incontinence (28%), as well as emotional alterations (p=0.006). Urinary incontinence was associated with insomnia (p=0.005).
CONCLUSION: Urinary incontinence was prevalent only in women and was not affected by COVID-19. Women also exhibited greater emotional alterations. Insomnia was the variable associated with the outcome. Thus far, there is incipient evidence regarding the association of the SARS-CoV-2 infection with the prevalence of urinary incontinence in individuals with Post-COVID-19 Syndrome.
A foam transfer device is described, for use with aerosol canister apparatus for producing a sclerosant foam for the treatment of, inter alia, varicose veins. The device enables diversion of an initial quantity of below-specification foam from the canister to waste, e.g. to an integral waste chamber, before dispensing a further quantity of foam for use in treatment. The switching of the flow from the waste chamber to a different outlet for use is accomplished without interrupting the flow from the aerosol canister since this would cause the foam to drop below specification again. The waste chamber may be transparent so that the foam entering it can be observed and a decision made by a user when to stop diverting foam to waste. Alternatively, the foam may be diverted automatically e.g. when a set time has elapsed or a set volume of foam dispensed. The foam for use is normally dispensed into a syringe for subsequent injection into a varicose vein of a patient.
BACKGROUND: The epicanthal fold (EF) is a semilunar skin fold located in the medial canthus in most Asians. The medial canthus fibrous band (MCFB) reportedly plays a critical role in EF formation. Variations in MCFB shape and size affect the severity and type of EF.
OBJECTIVES: We aimed to analyze MCFB variations in different types and severities of EF and explore the effect of the MCFB resection epicanthoplasty technique (MCFB epicanthoplasty).
METHODS: Surgical videos of 40 patients undergoing MCFB epicanthoplasty in our department were reviewed. The MCFB (area), transverse dimension, vertical dimension, upper eyelid direction length (UEDL), and lower eyelid direction length (LEDL) were measured. For aesthetic assessment, 37 patients were followed up for 6 months; intercanthal distance (ICD) and horizontal lid fissure length (HLFL) were measured. Preoperative and postoperative ICD/HLFL ratios were compared. Postoperative scar recovery was evaluated with the Patient and Observer Scar Assessment Scale. Statistical significance was set at P < .05.
RESULTS: The MCFB diameter and area were larger for severe EF than for moderate EF (P < .01). Patients with severe EF had larger LEDL than UEDL (P < .01). The tarsalis type had a larger LEDL than the palpebralis type with the same severity (P < .01). MCFB epicanthoplasty yielded favorable postoperative cosmetic effects and scar recovery. Postoperative ICD decreased, while HLFL increased compared to preoperative values (P < .001). The ICD/HLFL ratio was significantly lower postoperatively than preoperatively (P < .001). Postoperative ICD/HLFL ratio was 1.2:1.
CONCLUSIONS: The MCFB affects the severity and type of EF. MCFB epicanthoplasty effectively corrected moderate to severe EF.
A method for making debromohymenialdisine (DBH) 2 and analogs thereof is described. One embodiment of the present method first comprises forming hymenin 4, and then converting hymenin into DBH 2 as described herein. One such embodiment first comprises providing a compound having Formula (3) where R is independently selected from the group consisting of hydrogen and lower aliphatic, and X is independently selected from the group consisting of hydrogen and halogen. A compound having Formula (3), such as Compound 10 with R and X as hydrogen, is then converted to DBH 2 or an analog thereof. An alternative embodiment of the method comprises forming Compound 30 or Compound 32, which are then directly converted to DBH 2. Alternatively, Compound 30 can be converted to Compound 10, which is then subsequently converted to DBH 2 by reaction with a halogen in the presence of an acid. The method of the present invention can be used to make analogs of DBH 2, including alkoxy derivatives, such as Compound 12, and conjugated diene derivatives, such as Compound 14.
Subjects will be given BUP 32mg in 2 doses, and observed for at least 90 minutes after the 2nd dose. The whole process will take a total of about 3-4 hours including the consenting process. Subjects will be asked questions and be examined repeatedly. Subjects will have 4 in-person visits and a phone call in addition to review of medical records.
Transient global amnesia (TGA) is a neurological condition characterized by temporary memory loss and classically associated with a reversible unilateral punctate focus of restricted diffusion in the cornu ammonis 1 (CA1) region of the hippocampus. Historically, the lesions were considered to be transient in nature with no long-term imaging abnormality. However, more recent studies have challenged the concept that there are no long-term neurological sequelae. In line with this evidence, we explore the role of ultra-high-resolution imaging using 7 Tesla MRI to evaluate for long-term imaging abnormalities in a 63-year-old woman with a typical clinical course and acute TGA imaging findings. The 7 Tesla MRI revealed a residual lesion on susceptibility-weighted imaging (SWI) with evidence of gliosis and volume loss at the site of the acute lesion in CA1 eight months after the acute episode. This case challenges the traditional mantra of TGA as a fully reversible condition with no long-term imaging findings, suggesting the need for further research using ultra-high-field MRI to determine TGA's potential long-term imaging sequelae and any association with neurocognitive sequelae.
<P>PROBLEM TO BE SOLVED: To provide a toilet soap composition which is excellent in molding and punching workability at the time of manufacturing soap, softness at the time of use, smoothness, bubble forming and moisturing properties.  <P>SOLUTION: This toilet soap composition comprises 50-90 pts.wt. of a mixture containing a monoglyceride sulfonate of formula 1 and a fatty acid soap at the mixing ratio of 1:0.3-0.03:1, 1-12 pts.wt. of a fatty acid and 1-25 pts.wt. of a linking agent (plasticizer) or an excipient. The monoglyceride sulfonate contains not less than 60% of the one whose RCOO-portion is derived from lauric acid or myristic acid. In formula 1, R is a 7-21C alkyl and M is sodium, potassium, triethanol amine or ammonia.  <P>COPYRIGHT: (C)2008,JPO&INPIT
FIELD: insecticides, veterinary science. SUBSTANCE: the following components are mixed for the preparation preparing, wt.-%: cypermethrin, 0.1-1.0; amitraz, 0.1-1.0; dimethylsulfoxide 0.001-20.0; and polyethylene oxide, the balance. Preparation provides the most effective action on all ectoparasite classes and complete recovery from broad disease spectrum. Preparation shows low toxicity and high effectiveness and can be used against mites, fleas, Trichodectes and other extoparasites. Preparation has fitness time up to 5 years. EFFECT: enhanced effectiveness of preparation.
Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
The frequency of cardiovascular adverse reactions which require therapy is rare; hence, experience with their treatment is limited. Whenever severe hypotension or complete AV block occurs following oral administration of verapamil, the appropriate emergency measures should be applied immediately, e.g., intravenously administered isoproterenol HCl, levarterenol bitartrate, atropine (all in the usual doses), or calcium gluconate (10% solution). In patients with hypertrophic cardiomyopathy (IHSS), alpha-adrenergic agents (phenylephrine, metaraminol bitartrate or methoxamine) should be used to maintain blood pressure, and isoproterenol and levarterenol should be avoided. If further support is necessary, inotropic agents (dopamine or dobutamine) may be administered. Actual treatment and dosage should depend on the severity and the clinical situation and the judgment and experience of the treating physician.

To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
PURPOSE:To sustained release pharmaceutical obtained by coating 2- nitroxymethyl-6-chloropyridine or a clathrate compound thereof in beta-cyclodextrin with a release control film. CONSTITUTION:A sustained release pharmaceutical, obtained by coating a compound expressed by the formula or a clathrate compound thereof in beta- cyclodextrin with a release control film and capable of releasing the drug sustainedly as a sustained release microcapsule and maintaining the drug effect for a long time. The above-mentioned sustained release microcapsule is obtained by applying a coating film base, e.g. acrylic resin or cellulosic derivative without pH dependence, capable of controlling the release of the drug to a core granule containing the main drug. The core granule containing the main drug is obtained by forming the main drug, excipient, e.g. sucrose, lactose, white sugar or mannitol, and an additive, etc., into a granule. The ratio of the main drug in the core granule component is 10-70wt%, and the coating weight is 0.1-20wt%.
The standardized concentrated herbal extract granules TRA were the combination of "Tokoro Combination(Pi-Hsieh-Fen-Ching-Yin Extract Granules)" and "Rehmannia and Akebia Formula (Dao Chi San Extract Powder)". "Tokoro Combination" and "Rehmannia and Akebia Formula" in each one batch number were used, manufactured by Chuang Song Zong Pharmaceutical Co., Ltd., a famous GMP manufacturer of concentrated herbal extract granules in agreement with international standards. The TRA was prepared in small granules, including concentrated herbal extract granules of "Tokoro Combination"(50%) and "Rehmannia and Akebia Formula" (50%). Both medicines have already been approved by the Ministry of Health and Welfare in Taiwan as ethical drugs. TRA granules were packed in oblique glassine packages. The placebo was also prepared as granules by Chuang Song Zong Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of TRA. The chemical composition of TRA was analyzed and profiled by using a high performance liquid chromatography (HPLC). The major components were diosgenin, yamogenin, betulin, oleanolic acid, hederagenin, akeboside, β-sitosterol, stigmasterol, inositol, catalpol, glycyrrhizin, etc.
The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
<P>PROBLEM TO BE SOLVED: To provide an allergy inhibitor that uses an efficacy of amorphous paramylon being a substance obtained by changing a crystalline structure of paramylon.  <P>SOLUTION: The allergy inhibitor inhibits allergic diseases. The allergy inhibitor comprises amorphous paramylon obtained by making crystalline paramylon derived from euglena amorphous. The amorphous paramylon has a relative crystallinity to crystallinity of crystalline paramylon by X-ray diffractometry of ≤20%. The allergy inhibitor effectively inhibits atopic dermatitis, pollinosis, etc., being allergic diseases.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Systems and methods are provided for collecting, preparing, and/or analyzing a biological sample. A sample collection site may be utilized with one or more sample processing device. The sample processing device may be configured to accept a sample from a subject. The sample processing device may perform one or more sample preparation step and/or chemical reaction involving the sample. Data related to the sample may be sent from the device to a laboratory. The laboratory may be a certified laboratory that may generate a report that is transmitted to a health care professional. The health care professional may rely on the report for diagnosing, treating, and/or preventing a disease in the subject.
Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
PURPOSE: Myocardial fibrosis after myocardial infarction (MI) is one of the main causes of death in patients, but there is no effective treatment for myocardial fibrosis at present. Hence, it is important to elucidate the pathogenesis of fibrosis after MI and find therapeutic targets for regulating ventricular remodeling after MI.
METHODS: Differentially expressed gene analysis, weighted Gene co-expression network analysis (WGCNA) and differential gene analysis in cardiac fibroblasts (CFs) were performed on the MI-related data (GSE153485 and GSE210159) from the GEO database to screen the hub genes related to ferroptosis in MI. After the establishment of MI model in vivo and in vitro, the myocardial CFs were observed by Masson staining, hematoxylin-eosin staining, CCK-8, and Transwell, and the changes of LRRc17 and ferroptosis-related proteins were detected by qRT-PCR and Western blotting. The expression of ROS was detected by fluorescence dye method.
RESULTS: Three DEGs were identified in MI related to ferroptosis, among which LRRc17 was selected for subsequent study. In both in vitro and in vivo models of MI, we found a sustained downregulation of LRRc17 expression and the expression of ferroptosis-related proteins GPX-4 and xCT, but increased ROS expression and enhanced migration and viability of CFs. After oe-LRRc17 treatment, the expression levels of GPX-4 and xCT were restored, while ROS levels were inhibited, and the migration and viability of CFs were inhibited. After treatment with ferroptosis inducer Erastin, there were down-regulated expressions of GPX-4 and xCT, increased expression of ROS, and enhanced migration and viability of CFs.
CONCLUSION: LRRc17 affects ventricular remodeling by mediating ferroptosis in CFs to regulate the degree of fibrosis after MI.
Ocular Changes– Ocular changes have occurred more frequently than skin pigmentation and have been observed both in pigmented and nonpigmented patients receiving chlorpromazine usually for 2 years or more in dosages of 300 mg daily and higher. Eye changes are characterized by deposition of fine particulate matter in the lens and cornea. In more advanced cases, star-shaped opacities have also been observed in the anterior portion of the lens. The nature of the eye deposits has not yet been determined. A small number of patients with more sever ocular changes have had some visual impairment. In addition to these corneal and lenticular changes, epithelial keratopathy and pigmentary retinopathy have been reported. Reports suggest that the eye lesions may regress after withdrawal of the drug.

Since the occurrence of eye changes seems to be related to dosage levels and/or duration of therapy, it is suggested that long-term patients on moderate to high dosage levels have periodic ocular examinations.
Breast cancer (BC) is among the top three most prevalent cancers across the world, especially in women, and its pathogenesis is still unknown. Fatty acid β-oxidation is highly associated with breast cancer. Serpin family E member 1 (SERPINE1)-induced down-regulation of fatty acid β-oxidation can facilitate BC cell proliferation, invasion, and metastasis. In this paper, the difference of miR-30d-5p expressions in both cancerous tissues and para-carcinoma tissues was first detected. Next, the expressions of SERPINE1, long-chain acyl-CoA dehydrogenase (LCAD) and medium-chain acyl-CoA dehydrogenase (MCAD) in the aforementioned tissues were analyzed. Finally, miR-30d-5p mimics were supplemented to breast cancer cells to observe the miR-30d-5p effect upon breast cancer cells. Via immunofluorescence assay and Western blotting, it was found that cancerous tissues had lower expressions of miR-30d-5p, MCAD and LCAD and a higher expression of SERPINE1 than para-carcinoma tissues. The miR-30d-5p mimic group had a decreased SERPINE1 expression and increased MCAD and LCAD expressions compared with the NC group, thus inhibiting BC cell proliferation, invasion, and metastasis. To sum up, miR-30d-5p blocks the cell proliferation, invasion and metastasis by targeting SERPINE1 and promoting fatty acid β-oxidation. Preclinical studies are further required to establish a fatty acid β-oxidation-targeting therapy for breast cancer.
Postoperative ileus (POI) is caused by enteric neural dysfunction and inflammatory response to the stress of surgery as well as the effect of anesthetics and opioid pain medications. POI results in prolonged hospital stays, increased medical costs, and diminished enteral nutrition, rendering it a problem worth tackling. Many cellular pathways are implicated in this disease process, creating numerous opportunities for targeted management strategies. There is a gap in the literature in studies exploring neonatal POI pathophysiology and treatment options. It is well known that neonatal immune and enteric nervous systems are immature, and this results in gut physiology which is distinct from adults. Neonates undergoing abdominal surgery face similar surgical stressors and exposure to medications that cause POI in adults. In this review, we aim to summarize the existing adult and neonatal literature on POI pathophysiology and management and explore applications in the neonatal population.
An attenuated pseudomonasaeruginosa isolate especially CFCPA 10142 for formulating vaccine curing or preventing pseudomonas contagion is disclosed. Pseudomonasaeruginosa isolate is extracted from the infected patient and classified into 7 classes by Fisher-Devilin immunotype; only type 1 germ is selected, repeatedly dosed to experimental animals and  acclimatized to yield attenuated pseudomonasaeruginosa isolate CFCPA 10142 (KCCM 10029) which is not toxic in itself and attenuated for the cell wall protein to yield only antigen. Type 1 isolate is selected as the objective isolate on the basis that it is detected from the blood of more than 21% of pseudomonas infected patients. The acclimation to yield the attenuated pseudomonasaeruginosa isolate is repeated, commonly 3-7 times, until it shows the desired value of LD50. The desired LD50 value is more than 2.0 x 107 ,desirably 7.6 x 107 cells. CFCPA 10142 can be used for preparing pseudomonasaeruginosa vaccine by nurturing the germs in various sized fermenters having an optimum environment; yielding many isolates; treating the isolates by a series of processes; yielding cell wall protein; and finally treating them by ordinary vaccine preparation methods.